Fig. 1.

15d-PGJ₂exacerbated the doxorubicin-disrupted morphology in Caki-2 cells. Caki-2 was treated with 1 μM doxorubicin (Dox) in the absence or presence of 20 μM 15d-PGJ₂ for 24 h. (A) Morphologies were photographed by phase contrast. Scale bar=100 µm. (B) Cell viabilities were determined by MTT reducing activity. (C) Caki-2 cells were treated with 1 μM doxorubicin and/or 20 μM 15d-PGJ₂ in the absence (open columns) or presence (filled columns) of 10 μM GW9662. Cell viabilities were determined by MTT reducing activity. Data are expressed as means±SE. (n =6). ^**P<0.01, compared with control. ##P<0.01, compared with 15d-PGJ₂ alone.